Can we predict breast cancer resistance to hormone therapy?
NCT ID NCT06361940
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at why some hormone-receptor-positive breast cancers stop responding to hormone therapy. About 100 women with early-stage breast cancer will receive standard hormone treatment for 4-12 weeks before surgery. Researchers will analyze tumor samples to find changes in certain proteins that may signal resistance, aiming to improve future treatment choices.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Froedtert Hospital and the Medical College of Wisconsin
RECRUITINGMilwaukee, Wisconsin, 53226, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?